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Aim To perform a comparative analysis of the pharmaceu-
tical pricing and reimbursement systems in Croatia and the 
27 European Union (EU) Member States.
Methods Knowledge about the pharmaceutical systems 
in Croatia and the 27 EU Member States was acquired by 
literature review and primary research with stakeholders.
Results Pharmaceutical prices are controlled at all levels in 
Croatia, which is also the case in 21 EU Member States. Like 
many EU countries, Croatia also applies external price refer-
encing, ie, compares prices with other countries. While the 
wholesale remuneration by a statutorily regulated linear 
mark-up is applied in Croatia and in several EU countries, 
the pharmacy compensation for dispensing reimbursable 
medicines in the form of a flat rate service fee in Croatia 
is rare among EU countries, which usually apply a linear 
or regressive pharmacy mark-up scheme. Like in most EU 
countries, the Croatian Social Insurance reimburses spe-
cific medicines at 100%, whereas patients are charged co-
payments for other reimbursable medicines. Criteria for re-
imbursement include the medicine’s importance from the 
public health perspective, its therapeutic value, and relative 
effectiveness. In Croatia and in many EU Member States, re-
imbursement is based on a reference price system.
Conclusion The Croatian pharmaceutical system is similar 
to those in the EU Member States. Key policies, like exter-
nal price referencing and reference price systems, which 
have increasingly been introduced in EU countries are also 
applied in Croatia and serve the same purpose: to ensure 
access to medicines while containing public pharmaceuti-
cal expenditure.
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Since 1990, the Croatian health care system has changed 
considerably. Reforms were undertaken to totally re-or-
ganize the health care system by introducing privatiza-
tion of primary health care and institutional changes to 
increase efficiency and ensure accessibility and funding 
for health care (1-5). In 1999, the Croatian Institute for 
Health Insurance (CIHI), as key third-party payer, was set 
up (6), as well as another institution, the Agency for Me-
dicinal Products and Medical Devices, which started to 
work in 2003 (7). At that time, Croatia, which had been 
granted candidate status for the European Union (EU) in 
June 2004 (8), had already been working for years on har-
monizing its pharmaceutical legislation with the “acquis 
communautaire” (ie, accumulated legislation, legal acts, 
and court decisions, which constitute the body of Eu-
ropean Union law) (7). This concerned, in particular, the 
regulatory framework regarding marketing authorization 
that is harmonized in the EU (9). Further major compo-
nents of a pharmaceutical system, besides market au-
thorization,  are  pharmacovigilance,  pricing,  reimburse-
ment, and distribution; for all of which specific regulation 
is in place in most countries with a well-developed health 
system. In the EU, pharmaceutical pricing and reimburse-
ment remains the competence of the Member States. 
While all EU Member States have to comply with the rules 
of the Transparency Directive (10) which aims at guaran-
teeing pricing and reimbursement decisions to be taken 
in a transparent way within specific time-frames, it is up 
to the country how they shape their pharmaceutical pric-
ing and reimbursement system.
As part of their obligation to the fulfillment of the right to 
health, states have the obligation to grant access to essen-
tial medicines, ie, medicines that fulfill the priority needs of 
their population (11-13).
In many countries the world over, this is done by the provi-
sion of a rather limited range of medicines in public sector 
facilities that are procured by the state. While eligible pa-
tients can access essential medicines in the public sector 
either free of charge or with a modest co-payment, they 
have to purchase out-of-pocket medicines in the private 
sector (14-17).
Europe has higher health service coverage, ie, reimburse-
ment of health expenditure by a social health insurance or 
a national health service, compared with the rest of the 
world. This is reflected in the share of the public funding 
of health and pharmaceutical expenditure. In the EU, 
around 75% of health expenditure and two thirds of 
pharmaceutical expenditure is on average covered by the 
public payers (18). All EU countries have been struggling 
with the rise in pharmaceutical, in particular publicly fund-
ed, expenditure (Table 1).
Cost-containment is also an issue for high-income coun-
tries. They apply a range of supply-side and demand-side 
measures, both direct and indirect, targeting the price 
and/or the volume components. In the field of pricing 
and reimbursement, different frameworks for the regula-
tion of prices and distribution margins are in place and 
different methodological approaches and tools are ap-
TaBLe 1. Development of pharmaceutical expenditure in 
Croatia and in the european Union Member States, 2000-2005 
and 2000-2008 (or latest available year)
Index of pharmaceutical expenditure in
2000-2008 (index 
year 2000 = 100)
2005-2008 (index 
year 2005 = 100)
Country total public total public
Austria (AT) 156 156 120 125
Belgium (BE) n.a. n.a. 113 124
Croatia (HR) n.a. 152† n.a. 109†
Cyprus (CY) n.a. n.a. 127‡ 109‡
Czech Republic (CZ) 228 183 119   97
Denmark (DK) 150‡ 172‡ 112‡ 112‡
Finland (FI) 152‡ 172‡ 103‡ 108‡
France (FR) 149 148 111 107
Germany (DE) 138 146 110 114
Greece (EL) 268‡ 336‡ 136‡ 147‡
Hungary (HU) n.a. n.a. 111   97
Ireland (IE) 303 353 136 144
Italy (IT) 123 131 101   96
Latvia (LV) 212 248§ 156 122§
Lithuania (LT) 279‡ n.a. 142‡ n.a.
Luxembourg (LU) 139)) 142II n.a. n.a.
Malta (MT) 131‡ 220‡ 105‡ 122‡
Netherlands (NL) 154 153 116 116
Poland (PL) n.a. n.a. 135 136
Portugal (PT) 139§ 138§ 103§ 100§
Slovakia (SK) 254 220 134 130
Slovenia (SI) n.a. n.a. 116 112
Spain (ES) 207 206 119 121
Sweden (SE) 134 111 110 106
United Kingdom (UK) 116 125   96   97
*Source: OeCD Health Data 2010 (19), supplemented by data validation 
and data provision from PPRI network members (national statistics for 
Croatia, Cyprus, Finland, Lithuania, Latvia, Malta, Netherlands). Data 
are missing for Bulgaria, estonia, and Romania (n.a.).
†Social insurance expenditure on prescription medicines.
‡2000-2007 and 2005-2007, respectively.
§2000-2006 and 2005-2006, respectively.
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plied to assess which prices are considered acceptable 
for the public payer as well as for the individual. Most EU 
countries opted for price regulation for, at least, reim-
bursable medicines and regulation of wholesale and, in 
particular, pharmacy margins (18,20-32). Countries have 
been elaborating criteria (eg, cost-effectiveness, relative 
effectiveness, medical need) for deciding when and how 
much  reimbursement  should  be  granted.  Health  eco-
nomics, which is also referred to as “fourth hurdle” (33), 
has been increasingly used in European reimbursement 
decisions (34-36). With the institutionalization of health 
economics  in  pharmaceutical  reimbursement,  health 
technology assessment (HTA) has been gaining impor-
tance  as  a  basis  for  decision-making  (37).  Already  ob-
servable during the last decade, but reinforced by more 
recent literature (32,38,39), the tools of external price ref-
erencing (international price comparisons) and reference 
price systems (limitation of reimbursement for identical 
or similar medicines in a cluster) have been increasingly 
used in several EU Member States. Comparing the evi-
dence for the application of different policy options, nu-
merous changes could be observed that addressed the 
introduction or abolition of a measure as a whole as well, 
and also rather often, the way the instrument is designed. 
Each country has its own individual approach to framing 
its pharmaceutical pricing and reimbursement system for 
reacting to the challenges, and the way how they do this 
is influenced by culture and tradition (18).
In 2009 and 2010, Croatia substantially reformed its reg-
ulation on pharmaceutical pricing and reimbursement. A 
maximization of “value for money” was one of the major 
objectives strived for in the reform (40).
This article presents the current pharmaceutical pricing 
and reimbursement system in Croatia following the reform 
and explores its similarities and differences compared with 
other European countries. Since Croatia is candidate for the 
EU membership, the 27 EU Member States were taken as 
reference. The scope of harmonization to the acquis com-
munitaire from a regulatory framework is not addressed in 
this study.
MaTeRIaLS aND MeTHODS
Indicators for benchmarking pharmaceutical systems
Pharmaceutical pricing and reimbursement is one key area 
where regulators and public payers apply a bundle of poli-
cy measures to reconcile the goals of providing the popu-
lation with effective and new medicines and of meeting 
budgetary limits.
Analyses in both peer-reviewed and gray literature (20-
32,38,39) have been focusing on specific pharmaceutical 
pricing and reimbursement regulations and policy meas-
ures, which have been in place in numerous European 
countries.
We will survey these key “standard” policy measures for 
pharmaceutical pricing and reimbursement. As method-
ological framework we have chosen the Pharmaceutical 
Health  Information  System  (PHIS)  indicators  (41),  which 
can be considered as the most recent indicators for phar-
maceutical systems from a public health perspective in 
Europe. The PHIS indicators build on experience in this 
field since they were developed based on earlier indica-
tors projects, in particular on three European Commission 
commissioned projects: EURO-MED-STAT (42), SOGETI in-
dicators (43), and Pharmaceutical Pricing and Reimburse-
ment Information (PPRI) (18,44).
For  the  comparative  analysis  of  pharmaceutical  pricing 
and reimbursement in this article, we selected the follow-
ing PHIS (sub)indicators:
• with regard to pricing:
− price control at manufacturer level,
− key pricing policies at manufacturer level,
− external price referencing,
− price control at distribution level (wholesale, pharmacy).
• with regard to reimbursement:
− reimbursement eligibility,
− reimbursement lists (positive lists, negative lists),
− reimbursement rates,
− reference price system,
− co-payments.
Even if health and pharmaceutical expenditure have been 
defined among the three core indicators of the total of the 
23 PHIS indicators, expenditure data will not be presented 
in the Results section, which aims to focus on policy op-
tions. Data about pharmaceutical expenditure’s growth in 
European countries were provided as background infor-
mation in the Introduction section.
While the PHIS indicators’ methodology framework cov-
ers both the outpatient and inpatient sector, we ad-
dress only the outpatient sector.PUBLIC HEALTH 186 Croat Med J. 2011; 52: 183-97
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Information on the Croatian pharmaceutical system
A  review  of  international  literature  was  carried  out  by 
searching the Internet in general and, in particular, the 
PubMed database and Google Scholar. Search terms in-
cluded “pharmaceutical policy,” “medicines,” “pharmaceuti-
cal,” “pricing,” “reimbursement,” “Croatia,” “Europe,” “EU,” alone 
and in combination with each other. The review focused 
on studies published in English, but also considered docu-
ments in German. Furthermore, gray literature was taken in 
consideration, as well reports and materials recommended 
by interview partners. Furthermore, the bibliography of ar-
ticles and reports was checked for other relevant studies.
In addition, we contacted the CIHI, which is the nation-
al  competent  authority  for  pricing  and  reimbursement 
of medicines, and the Croatian Association for Pharma-
cists. In personal interviews with experts of the CIHI in au-
tumn 2009 important data were gained and compiled in a 
factsheet with information as of end of 2009 (45). In sum-
mer 2010, follow-up contacts with CIHI staff were made for 
clarification, validation of information, and for providing 
updates. Two authors from CIHI contributed to this paper 
as co-authors and are thus guarantors of correct current 
data on Croatia. The information on Croatia presented in 
this study is as of July 2010.
Information on the pharmaceutical systems in the 27 
eU Member States
Information about the pharmaceutical pricing and reim-
bursement systems in the EU Member States has been 
gathered for years and is available in the WHO Collaborat-
ing Centre for Pharmaceutical Pricing and Reimbursement 
Policies, established at the Health Economics Department 
of  the  Austrian  Health  Institute  (Gesundheit  Österreich 
GmbH), to which two of the authors are affiliated. How-
ever, we needed a specific update for this article.
In 2007/2008, the authors affiliated to Gesundheit Österreich 
did a primary research on key pharmaceutical pricing and re-
imbursement information. This was done in the course of the 
PPRI project, at that time an EU-funded project. We collected 
the information and data through country reports, the so-
called PPRI Pharma Profiles (25),  which were written accord-
ing to an outline around major indicators by country experts, 
coming mainly from national public authorities in the field of 
pharmaceutical pricing and reimbursement (the PPRI net-
work members). Data for the comparative analysis were 
validated and/or added by the PPRI members.
The data in this “pharmaceutical pricing and reimburse-
ment information system” established by the Health Eco-
nomics Department of the Austrian Health Institute (Ge-
sundheit Österreich GmbH) have been regularly updated.
One reason for constant monitoring is that the institute 
operates on a legal basis (46) the Pharma Price Informa-
tion (PPI) service (47) about pharmaceutical prices in all EU 
Member States since the institute is mandated to check 
prices submitted by manufacturers to the Austrian Pricing 
Committee (Austria applies external price referencing). For 
interpreting the prices correctly, we have to know and un-
derstand the underlying regulatory framework.
In order to present the most updated information and 
data in this article, we did an extra validation, and we ad-
dress the PPRI network members. Even if PPRI as an EU-
funded project came to its end in 2008, the PPRI network 
continues as a Member States-driven initiative and has 
even enlarged. It now covers national public pricing and 
reimbursement  agencies  in  37,  still  mainly  European, 
countries. The collection of most up-to-date information 
for this study consisted of two surveys. First, for the PPRI 
network  meeting  in  November  2009,  the  PPRI  partici-
pants were asked to outline in a poster their current phar-
maceutical pricing and reimbursement system according 
to the key indicators, which have been applied for this 
article, and the expected reforms as of 2010. Those coun-
tries that had announced major changes for 2010 were 
followed up in e-mail and telephone correspondence in 
the first months of 2010. Second, to be sure that we did 
not miss any reforms, we launched a so-called PPRI query 
in September 2010, asking in a structured format for pol-
icy changes (major measures were listed) of the first two 
quarters of 2010 and expected reforms for the rest of the 
year 2010. In addition of these two surveys, extra corre-
spondence and conversations were needed for clarifica-
tions as well as for checking on phone with participants 
who had not responded. The list of PPRI network mem-
bers is shown in Table 2.
To guarantee consistency with the time-frame of the infor-
mation collected for Croatia, we present the information 
about the EU Member States as of July 2010.
Terminology
This  article  is  consistent  with  the  PHIS  Glossary  (48), 
which is a major terminology resource on pharmaceuti-
cal policies.187 Vogler et al: Croatian and EU pharmaceutical systems
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ReSULTS
Pricing at manufacturer level
In most EU Member States, manufacturer prices are di-
rectly regulated by the state. However, in a few EU coun-
tries (Cyprus – for imported medicines, Denmark, Finland, 
Latvia, the Netherlands, Poland, Sweden, and United King-
dom) the manufacturer price is indirectly regulated, ie, with 
the maximum wholesale price being approved by the au-
thorities in the Nordic countries or via the Pharmaceutical 
Pricing Regulation Scheme (PPRS) scheme controlling the 
maximum profit of companies in the United Kingdom (32). 
Croatia controls the wholesale price and also indirectly the 
ex-factory price due to a statutorily regulated wholesale 
mark-up of maximum 8.5% on the ex-factory price.
At manufacturer level, Croatia and most EU Member States 
control pharmaceutical prices only for reimbursable med-
icines. Only 5 EU countries apply price regulation to all 
medicines (Table 3).
In Europe, Denmark and Germany (not taking into consid-
eration the reforms starting to be implemented in 2011) 
are  considered  as  the  two  most  liberal,  ie,  free-pricing 
countries (49,50). Nonetheless, there is a strong linkage be-
tween pricing and reimbursement in several systems (51), 
and this is also true for these two countries. In the reim-
bursement market, there is free pricing for on-patent med-
icines, but price control is applied for off-patent products.
The most common pricing policy is statutory pricing, where 
medicine prices are set on a legal basis (eg, law, enactment, 
decree) (48). This is the case in Croatia (Pricing Decree, Offi-
cial Gazette No. 155/09) and in a number of other Europe-
an countries. Price negotiations as single policy measure 
are rare; however, they are sometimes used in combina-
tion with statutory pricing (Table 3). Quite often, statu-
tory pricing is followed by a negotiation process be-
Country Institution
Austria (AT) Gesundheit Österreich GmbH / 
Geschäftsbereich ÖBIG – Austrian 
Health Institute (GÖG/ÖBIG) – PPRI 
Secretariat
Austrian Federal Ministry of Health 
(BMG)
Main Association of Austrian Social 
Security Institutions
Austrian Chamber of Labour
Belgium (BE) Health Insurance Institute
Bulgaria (BG) International Healthcare and Health 
Insurance Institute
Croatia (HR) Croatian Institute for Health Insurance
Cyprus (CY) Health Insurance Organization
Ministry of Health
Czech Republic (CZ) Ministry of Health
Medicines Agency
Charles University
Denmark (DK) Medicines Agency
Ministry of Interior and Health
Estonia (EE) Ministry of Social Affairs
Finland (FI) Ministry of Social Affairs and Health
France (FR) National Sickness Fund for Employees
Ministry of Health, Youth and Sport
University Claude Bernard Lyon 1
Germany (DE) Institute for Medical Documentation 
and Information
Ministry of Health
Greece (EL) Institute for Pharmaceutical Research 
and Technology
National Organization for Medicine
Hungary (HU) National Health Insurance Fund
Ireland (IE) Health Service Executive - Finance 
Shared Service
National Centre for Pharmacoeco-
nomics
Italy (IT) Medicines Agency
Latvia (LV) Centre of Health Economics
Lithuania (LT) Ministry of Health
Luxemburg (LU) Ministry of Health
Union of Sickness Funds
Malta (MT) Ministry of Social Policy, Health, the 
Elderly and Community
Netherlands (NL) Ministry of Health, Welfare and Sport
Poland (PL) Ministry of Health
Portugal (PT) Medicines Agency (INFARMED)
Romania (RO) Ministry of Health
Slovakia (SK) Medicines Agency
Ministry of Health
Slovenia (SI) Agency for Medicinal Products and 
Medical Devices
Spain (ES) Ministry of Health and Social Policy
Andalusian School of Public Health
Sweden (SE) Pharmaceutical Benefit Board
United Kingdom (UK) Medicines Pharmacy and Industry, 
Department of Health
*With regard to the focus of this article, only institutions from Croatia 
and the eU Member States are listed. additionally, 9 further countries 
and european and international institutions are also part of the PPRI 
network (see http://ppri.goeg.at).
TaBLe 2. Institutions participating in the Pharmaceutical Pricing and Reimbursement Information (PPRI) network*
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tween the public payer and the pharmaceutical company 
when it comes to reimbursement of medicines.
A common pricing procedure in the EU countries is exter-
nal price referencing (international price comparison). Ex-
ternal price referencing is also applied in Croatia. The bas-
ket of countries serving as reference for Croatia comprises 
Slovenia, Italy, France, and sometimes Spain and the Czech 
Republic (40,45). External price referencing is applied in 
22 EU Member States and usually the basket of reference 
countries is quite small (18,30,32).
Specific pricing policies often apply for generics, whose 
price in the reimbursement market is set at a certain per-
centage below the price of the original product (52). In 
Croatia, the first generic available will have the price set 
30% below the originator and each subsequent generic 
will be 10% below the previous generic on the Croatian 
positive list (29).
Pricing at distribution level
Pricing at distribution level refers to the remuneration of 
distributors (wholesalers and retailers) for their services of 
handling, distributing, and dispensing medicines.
In  Croatia,  a  statutory  maximum  wholesale  mark-up  of 
8.5% of the ex-factory price is applied (45). Seven EU Mem-
ber States also opted for regulating the wholesale remu-
neration via a linear add-on, whereas 14 countries apply a 
regressive mark-up scheme for wholesale (Table 4). In Cy-
prus (only for locally-produced medicines), Denmark, Fin-
land, the Netherlands, Sweden, and the United Kingdom, 
no statutory wholesale mark-up is in place at all (53).
Regarding the pharmacy sector, all EU Member States have 
implemented a statutory remuneration scheme. The most 
common one is the remuneration by a regressive mark-up 
scheme, but a few countries have decided for the policy 
option of offering (dispensing) fees or charges for the serv-
ices which a pharmacy performs (Table 4). Such a fee-for-
service remuneration can be found in Croatia, the Neth-
erlands, Slovenia, and the United Kingdom. In Croatia, the 
pharmacy  service  fee  is  calculated  on  granting  specific 
points for different services (eg, dispensing, accounting ac-
tivities, preparation of antibiotics of oral use) (45).
Pharmacists  in  Croatia  are  allowed  to  substitute  a  pre-
scribed medicine with a product of the same or cheaper 
price if the prescribed one is not on the market. Howev-
er, the reference price system, which is in place in Croatia, 
might motivate patients to ask for the least expensive al-
ternative, as the CIHI always pays the reference price.
Reimbursement eligibility
In Croatia, the competent authority for reimbursement is 
the CIHI, which acts as major third party payer for medi-
cines. Having been granted a marketing authorization, a 
pharmaceutical company may apply for reimbursement 
for its product at CIHI. In the reimbursement decision, the 
Reimbursement Committee acts as an advisory body that, 
TaBLe 3. Pricing policies and procedures at manufacturer 
level for medicines in Croatia and in the european Union (eU) 
Member States, 2010*
Pricing policies/procedure Croatia and eU Member States
Price control at manufacturer level:
for all medicines BE, CZ, EL, LU, LV†
for reimbursable medicines AT, DE‡, DK†, EE, ES, FI, FR, HU, HR, 
IE, IT, LT, PL, SE, SI, SK, UK§
for prescription-only medicines BG, NL†, PT, RO
others CYII, MT¶
Key pricing policies:
statutory pricing AT, BE, BG, CY, CZ, EE, EL, ES, FI, 
HR, LT, NL, PT, RO, SE, SI, SK
price negotiations FR, IT
other policy DE**, DK**, MT††, UK‡‡
mix of policies LV§§, HUII II, IE¶¶, PL§§
external price referencing:
in place AT, BE, BG, CY, CZ, EE, EL, ES, FI***, 
FR, HR, HU, IE, IT†††, LT, LU, LV, 
NL, PL, PT, RO, SI, SK
basket: <6 countries CY, EE, FR, HR, LT, LU, NL, PT, SI
basket: 6-12 countries BG, IE
basket: >12 countries AT, BE, CZ, EL, ES, FI***, HU, LV, 
PL, RO, SK
*Source: Survey by the authors, information provided by members of 
the Pharmaceutical Pricing and Reimbursement Information network. 
Country abbreviations are explained in the Table 1.
†at wholesale level.
‡Reimbursable off-patent products.
§National Health Service medicines.
IILocally produced medicines.
¶Public sector.
**Basically free pricing.
††Tendering (public sector).
‡‡Indirect price control through profit control based on Pharmaceuti-
cal Pricing Regulation Scheme.
§§Statutory pricing after price negotiations.
II IIPrice negotiations take place in addition to statutory pricing 
criteria.
¶¶The “statutory” basis is an agreement, in case of non-availability of 
data price negotiations take place.
***No formal price comparison, but prices of other eU Member States 
must considered.
†††Number of reference countries not specified.189 Vogler et al: Croatian and EU pharmaceutical systems
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following an evaluation of the application, recommends 
based on specified criteria if a medicine is eligible for reim-
bursement and on which of the two Croatian reimburse-
ment lists it should be placed. The final decision is taken by 
the board of the CIHI (45).
Such  an  approach  is  called  product-specific  reimburse-
ment (48), meaning that the third party payer (either a 
social  health  insurance  institution  or  a  national  health 
service) decides about the reimbursement eligibility of a 
specific medicine. This product-specific approach is also 
applied in 19 of the 27 EU Member States (eg, Belgium, 
Czech Republic, Greece, Finland, Italy, the Netherlands, Po-
land, the United Kingdom) (18,30,32).
The reimbursement eligibility of medicines could also be 
linked to diseases (eg, in the Baltic states, where the same 
medicine may be reimbursed at different rates depending 
on the indication) or to population groups, which is the 
key reimbursement eligibility scheme in Cyprus, Ireland, 
and Malta. In Denmark and Sweden, reimbursement cov-
erage increases with rising pharmaceutical consumption 
of a patient (expressed in her/his pharmaceutical expendi-
ture within a year), thus asking the patient to pay 100% of 
her/his medication at the beginning and offering (nearly) 
full reimbursement after a certain out-of-pocket spending 
threshold has passed – this is called consumption-based 
reimbursement  eligibility.  In  the  EU  countries,  the  key 
scheme, which is usually product-specific eligibility, might 
be  supplemented  by  another  scheme  (eg,  population 
group-specific  reimbursement,  since  higher  reimburse-
ment rates might be in place for vulnerable groups).
Reimbursement lists and reimbursement criteria
If in Croatia a medicine is considered eligible for reimburse-
ment, it will be put on one of the two positive lists:
• List A, which is the basic list providing 100% reimburse-
ment of the reference price for listed products (eg, Clexane, 
Amlopin, Simvastatin) or
• List B, where patients are charged co-payments (eg, Fosa-
max, Voltaren).
All EU countries have reimbursement lists. Positive lists, 
which include medicines that may be prescribed at the 
expense of a third party payer, are very common and are 
in place in 23 EU Member States (all but Germany, Greece, 
Spain, and the United Kingdom). Four countries (Germa-
ny, Hungary, Spain, and the United Kingdom) have neg-
ative lists which explicitly exclude medicines from reim-
bursement (18,30,32,53). Greece has provided a legal basis 
for negative lists, but has not implemented this measure 
yet. Indeed, Greece is currently considering the re-intro-
duction of the positive list, which had been abolished in 
2006 (Table 5).
Being included in the positive list does not automatically 
mean that the cost of the medicine will be fully covered 
by the third party payer. Like Croatia, many EU countries 
grant 100% reimbursement for selected medicines (eg, 
usually  essential  and  life-saving  medicines),  while 
TaBLe 4. Statutory wholesale and pharmacy remuneration 
in Croatia and in the european Union (eU) Member States, 
2010*
Statutory wholesale and pharmacy remu-
neration in Croatia and eU Member States
wholesale pharmacy
Scope:
for all medicines AT†, BE, CZ, EE, EL, 
ES, HR, HU, LU, LV, 
PT, SI‡
AT§, BE, CY – private 
sector, CZ, DKII, EE, EL, 
ES, FI¶, HR, HU, LU, LV, 
PT, SI‡
for reimbursable DE**, FR, IE††, IT, LT, 
PL, SK
DE**, FR, IE††, IT, LT, PL, 
SK, UK
for prescription-only 
medicines
BG, RO BG, NL, RO, SE
for others CY‡‡, MT§§ MT§§
Form:
linear CY, EL, HR, IE††, IT, 
MT, PL, PT
CY, DK, EL, ITII II, MT, PT
regressive AT, BE, BG, CZ, DE, 
EE, ES, FR, HU, LT, 
LV¶¶, RO, SI, SK
AT, BE, BG, CZ, EE, ES, FI, 
FR, HU, LT, LV¶¶, PL, RO, 
SE***, SK
fees - HR, NL, SI, UK
others LU††† DE‡‡‡, IE††, LU†††
*Source: Survey by the authors, information provided by members of 
the Pharmaceutical Pricing and Reimbursement Information network. 
Country abbreviations are explained in the Table 1.
†Two different schemes depending on reimbursement category.
‡except non-reimbursable over-the-counter.
§Two different schemes for different kind of customers.
IIexcept over-the-counter sold outside the pharmacy.
¶except nicotine replacement therapy sold outside the pharmacy.
**Two different schemes for prescription-only medicines and for 
reimbursable over-the-counter.
††For different reimbursement schemes.
‡‡For locally produced medicines.
§§For medicines in the private sector.
II IIMade regressive by mandatory pharmacy discounts.
¶¶Different schemes for reimbursable and for non-reimbursable 
medicines.
***Plus fee for generics.
†††Linear and regressive schemes depending on the origin of the 
product.
‡‡‡Flat fee plus linear mark-up for prescription-only medicines, 
regressive for reimbursable over-the-counter.PUBLIC HEALTH 190 Croat Med J. 2011; 52: 183-97
www.cmj.hr
other  reimbursable  medicines  are  reimbursed  at  lower 
rates, eg, at 75%, 50%, 40%, and 20% in Belgium (54) or at 
69%, 37%, and 15% in Portugal (55,56). Only in 7 EU Mem-
ber States are all medicines eligible for reimbursement fully 
reimbursed (Table 5).
In most European countries, the criteria for the decision on 
the inclusion of a medicine into reimbursement and the 
reimbursement rates are health-economic parameter. Usu-
ally the cost-effectiveness of a medicine, the medical need, 
the therapeutic value, in particular the relative effective-
ness (in case of medicines with no new, but added thera-
peutic value), and – increasingly, the budget impact (eg, in 
the Central and Eastern European countries) – are assessed 
(18,25,34-36).
In Croatia, a key criterion for inclusion into reimbursement 
is clinical effectiveness, which is defined as allows: impor-
tance of the medicine from a public health perspective, its 
therapeutic importance and its relative therapeutic value, 
ethical aspects and its quality, the reliability of data, and as-
sessment from reference sources. There is no formal HTA 
assessment in Croatia’s reimbursement system. All reim-
bursement applications for original medicines must con-
tain a budget impact analysis in line with the ISPOR guide-
lines (40).
Reference price system
Croatia has a reference price system, as do 20 EU Member 
States (Table 6). A reference price system is a pharmaceu-
tical reimbursement element in which identical or similar 
products are clustered in so-called reference groups. For 
each cluster, a maximum amount (reference price) to be 
covered by the third party payer is decided. The patient 
must pay the difference between this reference price and 
the actual pharmacy retail price of the medicine, in addi-
tion to any other co-payments.
In Croatia, the clustering is done based on a broad defini-
tion of a reference group, taking into consideration identi-
cal and similar products at ATC 5, 4, and 3 level (45). Most 
EU countries apply a rather strict understanding of a cluster, 
TaBLe 5. Reimbursement lists and rates and out-of pocket 
payments in Croatia and in the european Union (eU) Member 
States, 2010*
Reimbursement Croatia and eU Member States
Reimbursement lists:
positive list(s) AT, BE, BG, CY, CZ, DK, EE, FI, FR, HR, HU, IE, 
IT, LT, LU, LV, MT, NL, PL, PT, RO, SE, SI, SK
negative list(s) DE, EL†, ES, HU, UK
Reimbursement rates:
only 100% AT, DE, IE, IT, MT, NL, UK
100% and further 
rates
BE, BG, CY, CZ‡, DK, EE, EL, ES, FI, FR, HR, HU, 
LT, LU, LV, PL, PT, RO, SE, SI, SK
Co-payments/out-of-pocket payments 
(multiple types of co-payments possible):
fixed fee 
(eg, prescription fee)
AT, DK, EE, FI, FR, HR, HU, IT§, PL, SK, UK
percentag 
 co-payment
BE, BG, CY, CZ, DEII, DK¶, EE, EL, ES, FI, FR, 
HR, HU, LT, LU, LV, PL, PT, RO, SE¶, SI, SK
other out-of-pocket 
payments
IE**, MT††
*Source: Survey by the authors, information provided by members of 
the Pharmaceutical Pricing and Reimbursement Information network. 
Country abbreviations are explained in the Table 1.
†There is a legal basis, but the negative list has not been implemented 
yet. Currently, the re-introduction of positive list is ongoing.
‡No fixed rates defined except for bacterial/immune stimulants.
§In some regions.
IIIt is a prescription fee of 10% of the medicine’s price (with absolute 
minimum and maximum).
¶Depending on pharmaceutical expenses of the patient.
**Out-of pocket payments after a certain threshold of pharmaceutical 
expenses under a specific reimbursement scheme.
††In the private sector.
TaBLe 6. Reference price system in Croatia and in the 
European Union (EU) Member States, 2010*
Reference price systems Croatia and eU Member States
existence:
in place BE, BG, CZ, DE, DK, EE, EL, ES, FI, FR, 
HR, HU, IT, LT, LV, NL, PL, PT, RO, SI, SK
abolished SE
never introduced AT, CY, IE, LU, MT, UK
Clustering of reference groups:
at ATC 5 level BE, DK, EE, EL, ES, FI, FR, IT, LT, PT, RO, SI
at ATC 5 and 4 level BG†, CZ, HU†, SK
at ATC 5, 4 and 3 level and 
at different criteria
DE, HR, LV, NL, PL
Calculation of reference price:
lowest price of products 
in the group
BG, CZ, DE, DK, EE, FR, HU, HR, IT, LT, 
LV, PL, RO, SI, SK
below average of prices 
of products in the group
DE, ES, FI
(around) average (BE‡), EL, NL
above average PT
*Source: Survey by the authors, information provided by members of 
the Pharmaceutical Pricing and Reimbursement Information network. 
Country abbreviations are explained in the Table 1.
†anatomic Therapeutic Chemical classification 4 (aTC, http://www.
whocc.no/atc/structure_and_principles/) only for a few products.
‡The reference price is set at 30% below the price of the original prod-
uct in the cluster, which eventually leads to a reference price around 
the average of the prices of all products in the reference group, as the 
setting of the reference price is regularly followed by price decreases 
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which is built on products with the same active ingredient 
(ATC 5) and even the same pharmaceutical form (57,58).
Croatia decided to take as the reference product the low-
est priced product that accounts for at least 5% of the sales 
in the cluster, which is in line with the procedure chosen by 
the majority of the EU countries. Fifteen EU Member States 
reimburse at the level of the lowest price as well, while the 
remaining countries define the maximum reimbursement 
amount around and above the average of the prices of 
medicines in the group (Table 6).
The reference price system is regularly updated in Croatia. 
Frequent adaption to changes is also the case in many EU 
countries. Most of them update on a quarterly level, some 
even on a monthly level, and Denmark updates every two 
weeks (59).
Co-payments
Patients have to pay out of pocket for pharmaceutical ex-
penditure that is not covered by the state. This concerns 
private expenses for self-medication, but also any kinds of 
co-payments.
In Croatia, co-payments for medicines on the positive list 
B are applied. Additionally, a prescription fee of HRK 15 
(around € 2) per prescription is charged for reimbursable 
medicines. Finally, due to the reference price system, co-
payments may also occur if the patient opts for a product 
on List B with a price above the reference price (45).
Percentage co-payments are also the most common co-
payment in the EU countries (21 EU Member States), as 
most countries apply different reimbursement rates for the 
products on the positive list. Prescription fees are in place 
in 10 EU countries (Table 5). No co-payments at all (apart 
from those applicable under the reference price system) 
are charged in some regions in Italy, in the public sector in 
Malta, and in the Netherlands (18,30,32,51,59,60).
Usually, EU Member States have mechanisms for vulner-
able groups (eg, low income people, people with chronic 
diseases, etc.), which might take the form of lower reim-
bursement rates or exemptions from co-payments (61). 
In Croatia, specific medicines (in particular some orphan 
medicines)  are  excluded  from  co-payments,  since  the 
government runs a special budget for these medicines. 
The practice of having specific budgets for orphan medi-
cines or cost-intensive medicines, usually used in hospital 
settings, is also known from a few EU Member States (eg, 
France, the Netherlands) (62).
DISCUSSION
This study offers updated information on key features of 
the pharmaceutical pricing and reimbursement systems of 
28 European countries. We consider this piece of work to 
be of added value, since we provide not only recent infor-
mation on Croatia, whose pharmaceutical sector has been 
reformed substantially during the last two years, but also 
a complete and updated picture of all EU Member States. 
Evidence,  in  particular  peer-reviewed  literature,  is  often 
limited to a few EU countries, mostly large Western Euro-
pean countries. There have been in-depth overviews and 
analyses  of  pharmaceutical  pricing  and  reimbursement 
regulation in several EU countries around the millennium 
(20,21,23,24,26), but these pieces of information have be-
come out-dated following reforms which countries have 
undertaken,  and  the  EU  has  meanwhile  been  enlarged 
by 12 further countries. A highly appreciated exemption 
is some work on the generics sector which addresses the 
Central and Eastern European countries (28,29,58).
This study was performed for the out-patient sector. This is 
in line with most evidence in the literature (20,21,23,24,26), 
where the in-patient sector is disregarded completely or 
only few elements are considered. We believe that more at-
tention should be placed on the in-patient sector since the 
start of a treatment with a specific medicine has a major im-
pact on the further use in the out-patient sector. Nonethe-
less, in this article we addressed only the out-patient sector 
in order not to overload this study. We took this decision in 
the light of the fact that pricing and procurement policies 
and reimbursement strategies in the in-patient sector differ 
considerably from the out-patient sector (62).
Why is it of such relevance that the information is updat-
ed? Croatia has been implementing a set of policy meas-
ures to get better “value for money,” ie, to be able to grant 
best medication to the population within given financial 
limits. While between 2002 and 2008 an increase in CIHI 
expenditure for prescription medicines was observed for 
each year, Croatia succeeded in generating some savings 
in 2009 and 2010 (Figure 1).
At  the  same  time,  EU  Member  States  have  also  been 
struggling with growth rates in (public) pharmaceutical 
expenditure (Table 1). Cost-containment has been a 
major motivator for policy reforms in pharmaceuti-PUBLIC HEALTH 192 Croat Med J. 2011; 52: 183-97
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cal pricing and reimbursement in the EU Member States 
(20,21,23). The growth in (public) pharmaceutical expendi-
ture demands that countries react regularly, since meas-
ures that had been successful in short term lose its effec-
tiveness due to the “pendulum effect” (23) (ie, after some 
time, usually two to three years, players have learned the 
rules of the games and make use of loopholes in the sys-
tem). Besides striving for cost-containment, some EU Mem-
ber States have adapted their regulation of pharmaceutical 
pricing and reimbursement systems to comply with the 
European Commission’s legal requirements (ie, Transpar-
ency Directive). In its recent reform, Croatia, while having 
the focus on the pharmaceutical bill, also introduced cri-
teria for more transparency and accountability (eg, intro-
duction of a court instead of an arbitration procedure for 
appeal of the Social Insurance’s reimbursement decision) 
(40). This appears to be a good preparation for future ac-
tion within the EU regulatory framework.
On the pricing side, Croatia applies price regulation for re-
imbursable medicines at manufacturer level, as do many 
EU countries. A pricing procedure which has been increas-
ingly applied for regulating prices is external price regula-
tion (international price comparison). The updated infor-
mation in the article shows that today this procedure is 
used in 22 countries, some of which introduced it in the 
course of the last 10-15 years (18,23,32).
European  countries  have  increasingly  opted  for  imple-
menting this tool in spite of criticism. International price 
comparisons  are  considered  extremely  sensitive  to 
choices made about certain key methodological issues, 
such as sample selection, unit of measurement for 
price and volume, the relative weight given to consump-
tion patterns in the countries being compared, and the 
use of exchange rates or purchasing power parities for 
currency conversion (63,64). It has been suggested that 
prices should be weighted by consumption when being 
used for international price comparison. However, this is 
not the case in any European country. It would probably 
entail a lot of administrative work including high costs for 
acquiring the consumption data. Another concern about 
external price referencing is that it is considered as “readily 
game-able by the pharmaceutical industry” (38) and might 
contribute – by reducing pharmaceutical companies’ will-
ingness to price to market – to access and affordability 
problems in lower-income countries due to launch delays 
(65). Given the provided information and the design of this 
study, we cannot assess if this has been or will be problem 
for Croatia. In any case, we have not been made aware of 
such problems in Croatia yet.
An analysis (18) of external price referencing in Europe re-
vealed that countries tend to focus on a rather small bas-
ket of reference countries, and they tend to chose neigh-
boring countries, countries with which they have historical 
links and economic relationships and – in particular if they 
themselves rank among middle- or low-income countries 
– countries with a more or less low pharmaceutical price 
level. Some countries have a rather well-defined meth-
odology in the legal framework, while others allow some 
flexibility. Analyzing the methodology applied for exter-
nal price referencing, similarities of the Croatian system to 
the EU countries were identified: Croatia has a quite small 
basket of reference countries, however allowing the inclu-
sion of a few further countries, and it focuses on low-price 
countries. The current framework of external price refer-
encing in Croatia appears to offer a greater potential for 
savings.
In the field of distribution, the Croatian regulatory frame-
work is partly similar to the EU countries, with regulated 
maximum allowed remuneration for both wholesalers and 
pharmacies. To remunerate pharmacies, Croatia opted for a 
performance-based system (fee-for-service remuneration), 
which is rather rare in EU countries, only seen in Croatia’s 
neighboring country Slovenia and – to some extent – in 
the Netherlands and UK. Whereas a pharmacy’s remunera-
tion, organized as a margin scheme, is based on the prices 
of the medicines dispensed, a fee for service remunera-
tion takes the broader range of pharmacy services into ac-
count. While regulated mark-ups and margins continue to 
be the major form of regulating pharmacy remuneration in 
Figure 1.
expenditure  on  prescription  medicines  of  the  Croatian  Institute  for 
Health Insurance (CIHI) 2000-2010, expressed in million Croatian Kuna (€   
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Europe, performance-based remuneration might be one 
option which EU countries could consider and implement 
when re-organizing the pharmacy sector.
Regarding reimbursement, health economics, considered 
as “fourth hurdle” (33), plays an increasingly important role 
in Europe (34-36). This is also reflected in the current reim-
bursement legislation in Croatia in which, for instance, a 
budget impact analysis is asked for. A key element in the 
Croatian reimbursement system is a reference price sys-
tem, which has been introduced in more and more coun-
tries (66). While referencing pricing was identified for only 
5 EU Member States (out of the EU-15 Member States at 
that time) a decade ago (21), the present update shows 
that it is in place in 20 EU Member States (thereof 10 coun-
tries which were EU Member States at the time of EU-15). 
The rather late introduction of a reference price system 
in some EU countries can be attributed to the fact that 
for building clusters in the reference price system a suffi-
cient number of generics has to be on the market (67). In 
several, in particular Western European, countries it took 
some years until, due to the expiry of patents, this criti-
cal number became available, while Central and Eastern 
European countries, including Croatia, have always had a 
stronger generics market (18,29). There is evidence that 
the existence of rather broad clusters combined with low 
reference prices contributes to optimizing savings (59). In 
fact, Croatia applies a broad definition of a reference group 
whereas most EU countries opted for sticking to a rather 
strict scope of a cluster.
A reference price system is usually seen as one policy op-
tion within the bundle of measures for generic promotion 
(68,69), since it is a tool, if well designed, for developing and 
promoting a generics market (70). A study (18) provided evi-
dence that in Europe the instruments of generic substitution 
and reference price system usually go hand in hand because 
these two tools influence each other positively. Croatia also 
opted for this approach and implemented both tools. None-
theless, generic substitution in Croatia is neither mandatory 
nor motivated by a financial incentive that could serve as a 
positive factor for increasing generic uptake (59). However, 
in Croatia incentives for generic promotion are not consid-
ered necessary since the Social Insurance pays the reference 
prices, and as a consequence most manufacturers lower 
their prices to avoid co-payments.
This paper presents an analysis at macro level, ie, based 
on benchmarks for describing a pharmaceutical pricing 
and reimbursement system. It might be limited in its con-
clusions, since for performing a comparison of nearly 30 
countries we needed to compromise in some cases and 
simplify the presentation of data in order to achieve clarity. 
The study does not provide answers on the success and 
failure of specific policy measures implemented in Croatia. 
There are indications of a positive impact of the recent 
pharmaceutical  pricing  and  reimbursement  reform  on 
public pharmaceutical expenditure, but the middle- and 
long-term effects on expenditure, and also on accessibility 
and affordability for the patients can be only be assessed in 
the coming years. Such an evaluation should consider the 
whole spectrum of the Croatian pricing and reimburse-
ment reform. Besides the policies described in this study 
and included in the comparison, the reform covered fur-
ther important elements: improvements in decision-mak-
ing and transparency have been made, eg, applications for 
the inclusion of products are now published on the Web 
site. Importantly, Croatia has been addressing the sensitive 
issue of expensive medicines and provided for a separate 
budget for these expensive medicines and for a payback 
agreement mechanism between the manufacturers and 
the Social Insurance (40,45).
Croatia has been undertaking reforms in the pharmaceu-
tical system for more than 10 years. Apart from changes 
in the marketing authorization procedure (6) and in pric-
ing and reimbursement, reforms have been made to shape 
the system for ensuring a more rational use of medicines. In 
the last years, a focus has been placed on improving physi-
cians’ prescribing pattern, which was considered as exten-
sive. This was addressed by awareness-raising projects and 
performance indicators in the contracts (71,72). A major 
current issue in Croatian pharmaceutical policy concerns 
promotional  activities  by  pharmaceutical  companies.  In 
the 2009/2010 reform, a uniform agreement on the ethical 
promotion of medicines was introduced on a mandatory 
basis, and its implementation is guaranteed by a financial 
revolving deposit mechanism where pharmaceutical com-
panies are obliged to deposit their promotional budgets to 
the Social Insurance (40).
The comparison in this article did not tackle all aspects of a 
pharmaceutical system.
Our comparative exercise is a starting point for assessing 
where Croatia stands regarding its pharmaceutical pric-
ing and reimbursement framework in Europe and which 
countries with a similar organization of the pharmaceuti-
cal system Croatia could address for exchanging infor-
mation and experiences about policy options.PUBLIC HEALTH 194 Croat Med J. 2011; 52: 183-97
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This scene-setting might serve as a good basis for an 
in-depth analysis that looks more closely at some poli-
cy measures and combines indicators. For instance, the 
fact that a country has a positive list is a preliminary in-
dicator  of  access  to  medicines,  however  the  number 
and the kind of medicines selected to be included in 
the positive list and the reimbursement rates have also 
be taken into consideration in a more detailed assess-
ment (73). The PHIS indicators proved to be an adequate 
instrument for this comparative analysis; however, the 
reimbursement criteria (eg, role of health economics) 
should be more highlighted and could be defined as an 
indicator of its own.
Conclusion
Each health and pharmaceutical system has its own coun-
try-specific  characteristics  which  have  been  established 
due to historical developments, traditions, and culture. As a 
result, there are 27 pharmaceutical pricing and reimburse-
ment systems in the EU.
Even if the individual organization of the pharmaceutical 
system differs in its details among the countries, some pat-
terns and trends can be observed. In the EU Member States, 
external  price  referencing  as  a  procedure  for  setting  the 
price of medicines and reference price systems for limiting 
the  reimbursement  amount  have  become  increasingly 
used instruments. Both policy measures are also in place 
in Croatia, since Croatia has to address the same challenge 
as the EU countries, namely fostering prompt, affordable 
access to the latest effective medicines within financial re-
straints. For successfully containing public pharmaceutical 
expenditure in the long run, countries have to adapt their 
policies continuously. Indeed, EU Member States are in the 
process of re-shaping their pharmaceutical policy frame-
works on a regular basis. Croatia has recently launched a 
major reform which has led to savings in pharmaceutical 
expenditure.
It is recommended that Croatia closely monitor and evalu-
ate the effects of the newly introduced policy measures 
on the development of pharmaceutical expenditure at 
the expense of the Social Insurance and the patients in 
order to assess the impact of the reform on accessibility 
and affordability. Some further areas should be looked at. 
We identified as major research issues to be addressed 
the volume component (data on the consumption of 
medicines, policy options for promoting a more ration-
al prescribing and use of medicines) as well as the 
hospital pharmaceutical sector with its impact on overall 
pharmaceutical expenditure and the functioning of the 
interface management.
Croatia has developed a modern pharmaceutical pricing 
and reimbursement system which appears to be able to 
react to the challenges of patients’ needs within given fi-
nancial limits. The way the system is organized is similar 
and comparable to the countries of the EU. This allows 
Croatia’s authorities and institutions to actively participate 
in  European  networks.  Croatian  authorities’  staff  is  en-
couraged to continue sharing their experiences on policy 
measures with their colleagues in other countries, since 
such networking is a fruitful exercise allowing all involved 
parties to learn lessons from each other.
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